A total of 108 adults with T1D participated in a randomized, double-blind, placebo-controlled experiment to examine the effects of short-acting exenatide on cardiovascular disease indicators in conjunction with insulin therapy. The gene discussed is INS; the disease is type 1 diabetes mellitus.